These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27839923)

  • 21. Fasting and post-prandial glucose and diabetic complication. A meta-analysis.
    Monami M; Adalsteinsson JE; Desideri CM; Ragghianti B; Dicembrini I; Mannucci E
    Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):591-8. PubMed ID: 23711419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
    Neal B; Perkovic V; Mahaffey KW; Fulcher G; Erondu N; Desai M; Shaw W; Law G; Walton MK; Rosenthal N; de Zeeuw D; Matthews DR;
    Diabetes Obes Metab; 2017 Jul; 19(7):926-935. PubMed ID: 28244644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps.
    Paneni F
    Diab Vasc Dis Res; 2014 Jan; 11(1):5-10. PubMed ID: 24254974
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    Staels B
    Am J Med; 2017 Jun; 130(6S):S30-S39. PubMed ID: 28526184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes.
    Packer M
    Diabetes Obes Metab; 2018 May; 20(5):1089-1095. PubMed ID: 29316137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
    Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
    J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes.
    Laffin LJ; Bakris GL
    Diabetes Obes Metab; 2018 Jun; 20(6):1335-1336. PubMed ID: 29424470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
    Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
    Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
    Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
    J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Which person with diabetes should receive cardioprotective glucose-lowering medicines?
    Bloomgarden ZT
    J Diabetes; 2020 May; 12(5):352-353. PubMed ID: 32119186
    [No Abstract]   [Full Text] [Related]  

  • 32. Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
    Williams KH; Sullivan DR; Nicholson GC; George J; Jenkins AJ; Januszewski AS; Gebski VJ; Manning P; Tan YM; Donoghoe MW; Ehnholm C; Young S; O'Brien R; Buizen L; Twigg SM; Keech AC
    Metabolism; 2016 May; 65(5):783-793. PubMed ID: 27085785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.
    Kim HJ; Kim DJ
    J Diabetes Investig; 2017 Jul; 8(4):431-433. PubMed ID: 27930863
    [No Abstract]   [Full Text] [Related]  

  • 34. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
    DeFronzo RA; Chilton R; Norton L; Clarke G; Ryder RE; Abdul-Ghani M
    Diabetes Obes Metab; 2016 May; 18(5):454-62. PubMed ID: 26919068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
    Bouchi R; Nakano Y; Fukuda T; Takeuchi T; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Endocr J; 2017 Mar; 64(3):269-281. PubMed ID: 27916783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease.
    Boronat M; García-Cantón C; López-Ríos L; Quevedo V; Lorenzo DL; Batista F; Riaño M; Nóvoa FJ
    Diab Vasc Dis Res; 2014 Jan; 11(1):53-9. PubMed ID: 24254975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardioprotective effects of glucagon-like peptide 1 receptor agonists].
    Ametov AS; Kamynina LL; Akhmedova ZG
    Kardiologiia; 2014; 54(7):92-6. PubMed ID: 25177820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EMPA-REG - the "diuretic hypothesis".
    McMurray J
    J Diabetes Complications; 2016; 30(1):3-4. PubMed ID: 26597600
    [No Abstract]   [Full Text] [Related]  

  • 39. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton R
    Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.